LGND vs IMVT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LGND · Ligand Pharmaceuticals$286.85 ▼ 0.03%
IMVT · Immunovant$31.77 ▼ 2.31%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LGND +38.6%
- IMVT +36.2%
Head to head
| Metric | LGND | IMVT |
|---|---|---|
| Price | $286.85 | $31.77 |
| Change today | ▼ 0.03% | ▼ 2.31% |
| Market cap | $5.74B | $6.57B |
| Return, 3 months | +2.4% | -26.7% |
| Return, year to date | +51.7% | +25.0% |
| Return, 1 year | +44.0% | +40.6% |
| P/E (TTM) | 115.2 | – |
| P/B | 6.0 | 10.0 |
| P/E percentile vs own 5y | 99th | 28th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -31.8% | – |
| Net profit growth (YoY) | -124.3% | +23.1% |
| Gross margin | 95.2% | – |
| Operating margin | 14.4% | – |
| Net margin | 20.3% | – |
| Return on equity | 5.4% | -86.5% |
| Analyst target vs. price | +27.9% | +52.4% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 39 | 48 |
| 30-day volatility | 38.6% | 62.7% |
| Max drawdown, 1 year | -14.7% | -40.5% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IMVT is the largest of the group by market value.
- LGND has returned the most over the past year.
- LGND has been the calmest stock over the last 30 days.